Imiquimod 5% cream for the treatment of actinic keratoses.
Actinic keratoses (AKs) are premalignant inflammatory skin lesions with the potential to transform into squamous cell carcinoma (SCC). There are several treatment options available for patients presenting with multiple AKs. Imiquimod is believed to stimulate and enhance host immune responses locally against skin tumors and viral infections. Five clinical studies to date have demonstrated its safety and efficacy in the treatment of actinic keratoses. Long-term follow-up studies examining recurrence rates are limited.
Division of Dermatology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
N
N
Somani
J K
JK
Rivers
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000634:Aminoquinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000077271:Imiquimod; D007642:Keratosis / Q000188:drug therapy*; D010778:Photochemotherapy
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000077271:Imiquimod